The Gamma Knife Radiosurgery Center
Trigeminal neuralgia (TN) is caused by pressure on the trigeminal nerve which produces agonizing sudden bursts of face pain in areas effected by the trigeminal nerve. Most of the 140,000 people with the condition have pain on just one side of the face, but 5-10% of all cases can experience pain on both sides of the face.
Gamma Knife radiosurgery has become one of the best standard treatments for this condition, due to its effectiveness and extremely low risk of complications. It is the only radiosurgical option for which positive results have been established in peer-reviewed journals.
- 85-90% Pain Relief
- Used for patients who cannot tolerate or have difficulty with medications.
Patients who undergo Gamma Knife as a treatment for Benign Tumors appreciate the fact that it is an outpatient procedure and that following one to two days of treatment, they can return to their normal daily routines. The Gamma Knife is emerging as a standard of care for patients suffering from benign brain tumors, especially because of it pinpoint targeting ability.
Meningiomas make up about one-fifth of all primary intracranial tumors, and are slow growing tumors that that arise from the tissue that lines the brain.
" 95-97 % Tumor Control Rate for Benign Meningiomas
" Primary or secondary treatment modality
Thousands of people have received Gamma Knife radiosurgery for their pituitary tumors. The tumors are found behind and between the eyes at the base of the brain, just beneath the hypothalamus to which it is connected by a thin stalk.
- 65-85% Tumor Control Rate for Secretory Tumors
- 90% Tumor Control Rate for Non-Secretory Tumors
- Primary or secondary treatment modality
The Gamma Knife's 201 beams of radiation converge on the malignant tumor target site(s), resulting in a high dose of radiation delivered to the target site with a sharp dose gradient at the target edge. Used as a complimentary, outpatient treatment option, survival rates can exceed those previously reported for surgery with whole brain radiation or whole brain radiation alone. The Gamma Knife provides added advantages of lower morbidity, greater flexibility in terms of local and number of tumors treated, and the ability to treat patients multiple times for the development of new lesions.
Brain Metastases (single or multiple lesions)
The most common type of brain tumor is a brain metastases. The most common source of brain metastases are lung, breast, renal and colon tumors.
- 95-98 % tumor control rate for all types of Metastases
- Can use radiosurgery along or in combination with whole brain radiation therapy
Gliomas are malignant brain tumors that arise from the glial tissue in the brain and invade surrounding normal brain tissue. They usually grow rapidly. Gliomas account for 45-50% of all primary brain tumors.
- Can use as primary, secondary or as a boost following surgery
- Low rate of complications
Acoustic neuromas account for 6% of all primary intracranial tumors. They are usually benign and slow growing. Acoustic neuromas are skull based nerve sheath tumors that are found in the vestibular portion of the VIII cranial nerve.
Gamma Knife is an excellent initial treatment choice because both short-term and long-term risks are minimal. When used to treat acoustic neuromas, the Gamma Knife virtually eliminates the risk of permanent facial weakness and the need for further surgery to restore proper facial functioning.
- 90-95% Tumor Control Rate
- 50-75% of patients benefit from preservation of hearing
- Appropriate as primary or secondary source of treatment
Vascular Disorders - Arterial Venous Malformation (AVM)
AVM is described as a web of dilated blood vessels that disrupt normal blood flow to the brain. AVM is the leading cause of stroke in younger people.
Gamma Knife has become the gold standard for AVM treatment. It allows
those suffering from AVM to return to all activities very soon after
treatment, involves minimal risk and is a proven financially effective
- 80-90% obliteration (2 years)
- Single and/or staged treatment options
- Initial treatment modality